Pathline's COVID-19 testing is now available. Learn More.

CDH17

Alias/Synonym: Cadherin 17, Gastrointestinal Adenocarcinoma

CPT Code: 88342

Includes:
Specimen Type, Preferred:
Formalin fixed paraffin embedded tissue
Specimen Type, Alternate:
Sample Quantity, Preferred:
1 block
2 slides
Sample Quantity, Minimum:
N/A
Transport Container:
Paraffin block
Unstained slides
Transport Temperature:
Room temperature
Collection Instructions:
Block and slide identifiers should be clearly written and match exactly with the specimen ID and specimen labeling as noted on the requisition.
Slides should be positively charged and cut at 3-4 microns for each stain/antibody ordered.
Specimen Stability:
N/A
Rejection Criteria:
No liquid specimens.
Uncharged slides
Clinical Significance:
CDH17 (Cadherin 17 or LI-cadherin) is a cell adhesion molecule expressed in intestinal epithelium, transcriptionally regulated by CDX2. CDH17 is a highly specific marker in colon cancer (99/99, 100%) and is a more sensitive marker than CDX2 (93/99, 94%) and CK20 (91/99, 92%). It is present in some pancreatic and biliary adenocarcinomas and may be present in approximately 9-14% of lung adenocarcinomas. Overexpression of CDH17 (and conversely, underexpression of CDX2) correlates to poor prognosis in patients with epithelial ovarian cancer. CDH17 may be helpful for early diagnosis of Barrett’s esophagus. CDH17 has been shown to be a useful marker for distinguishing between primary urinary bladder adenocarcinoma and urothelial carcinoma with glandular differentiation. Note that it does not distinguish primary urinary bladder adenocarcinoma from colorectal adenocarcinoma secondarily involving the bladder.
Limitations:
Turnaround Time:
1 day(s)
Reference Ranges:
N/A